# Michael Severino

> Michael Severino is Sarepta Therapeutics’ chief executive officer and a board member, appointed effective July 28, 2026. His career includes senior leadership at Merck, Amgen and AbbVie, followed by the CEO role at Tessera Therapeutics and a CEO-Partner role at Flagship Pioneering. A University of Maryland biochemistry graduate with an M.D. from Johns Hopkins, he has led international organizations and serves on several corporate boards.

- **Role:** Chief Executive Officer at Sarepta Therapeutics
- **Organizations:** Sarepta Therapeutics, Tessera Therapeutics (former CEO), Flagship Pioneering (former CEO-Partner), AbbVie (former vice chairman and president), Amgen (former senior executive), Merck & Co. (former senior director), Avantor (director), Viatris (director), Montai Therapeutics (director), Quotient Therapeutics (director), Field Museum (board service, 2015-2022)
- **Education:** B.S. in Biochemistry; summa cum laude; Phi Beta Kappa, University of Maryland, College Park, M.D.; Alpha Omega Alpha Honor Medical Society, Johns Hopkins University, Residency and postdoctoral training, Massachusetts General Hospital and Harvard Medical School
- **Known for:** Led an Amgen organization of more than 2,000 people across 35 countries., Promoted from AbbVie’s research chief to vice chairman and president, with responsibility for R&D, human resources, operations and corporate strategy., Graduated summa cum laude from the University of Maryland and joined Phi Beta Kappa.

## Career timeline

- **1987** — Graduated from the University of Maryland with a biochemistry degree.
- **1998** — Moved into industry at Merck & Co.
- **2004** — Joined Amgen as a senior director.
- **2007** — Promoted to vice president, Global Development, at Amgen.
- **2012** — Named senior vice president, Global Development, and corporate chief medical officer at Amgen on February 14.
- **2014** — Joined AbbVie as executive vice president, R&D, and chief scientific officer.
- **2018** — Became AbbVie vice chairman and president in December.
- **2020** — Joined Avantor’s board in April.
- **2022** — Became Tessera CEO and Flagship Pioneering CEO-Partner; Tessera appointment announced June 2.
- **2025** — Joined Viatris’s board in May.
- **2026** — Became Sarepta CEO and board member effective July 28.

## Achievements

- Led an Amgen organization of more than 2,000 people across 35 countries.
- Promoted from AbbVie’s research chief to vice chairman and president, with responsibility for R&D, human resources, operations and corporate strategy.
- Graduated summa cum laude from the University of Maryland and joined Phi Beta Kappa.
- Chairs Avantor’s compensation and human resources committee.

## Latest updates

- **2026-07** — Sarepta announced his appointment on July 27; he became CEO and a board member July 28, succeeding Doug Ingram.
- **2025-05** — Joined Viatris’s board of directors.

## Links

- Website: https://www.sarepta.com/about-us/leadership/michael-severino-md
- LinkedIn: https://www.linkedin.com/in/michael-e-severino

---

Profile page: https://yespress.io/michael-severino
Published by YesPress — https://yespress.io
Last updated: 2026-10-22